Gilead Sciences (GILD) Estimates, PT Lowered at Baird

October 18, 2016 6:58 AM EDT
Get Alerts GILD Hot Sheet
Price: $72.42 -0.58%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade GILD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird analyst Brian Skorney lowered 3Q16 Hep C estimates and his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $100.00 (from $122.00) on Rx data analysis.

Skorney commented, "As questions about the durability of Hep C sales plague GILD shares, we've taken a deeper look into the pace of U.S. Hep C prescriptions this quarter to adjust our model. Encouragingly, trends indicate that core new prescriptions (i.e., ex-Epclusa) may be stabilizing. We have modestly adjusted our 3Q16 revenue estimates for Gilead's portfolio, and continue to think consensus is setting them up for another miss on Hep C. We are lowering our target price to $100."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $72.64 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment